Abstract Number: 1873 • 2012 ACR/ARHP Annual Meeting
Clinical Characteristics and Health Care Utilization Patterns Among Patients with Fibromyalgia Newly Prescribed Amitriptyline, Duloxetine, Gabapentin or Pregabalin: A Large Cohort Study
Background/Purpose: Patients with fibromyalgia (FM) tend to use a number of different medications and have high health care costs. Treatment for FM generally consists of…Abstract Number: 1874 • 2012 ACR/ARHP Annual Meeting
Genomic Categories of Fatigue in Women with Fibromyalgia
Background/Purpose: FM is the chronic experience of body-wide pain, fatigue, cognitive dysfunction, and disordered sleep that occurs in the absence of any clear cause. Fatigue…Abstract Number: 1875 • 2012 ACR/ARHP Annual Meeting
A Patient and Physician Survey of Impact and Management of Fibromyalgia Across Latin America and Europe
Background/Purpose: Differences in healthcare practices around the world have been reported; however any impact on management of chronic conditions is often unclear. We surveyed patients…Abstract Number: 1876 • 2012 ACR/ARHP Annual Meeting
The Assessment and Treatment of Nonsurgical Periarticular Post-Traumatic Soft Tissue Injuries of the Knee
Background/Purpose: In spite of the fact that periarticular post-traumatic soft tissue injuries of the knee were considered less important than the knee joint pathology itself,…Abstract Number: 1877 • 2012 ACR/ARHP Annual Meeting
Is the Amount of T and B Lymphocytes, Natural Killer Cells and Macrophages in Biopsies From Non-Ruptured Chronic Tendinopathic Achilles Tendons Predictive for Long Term Outcome? A >3 Years Prospective Study of 37 Patients
Background/Purpose: In biopsies from non-ruptured chronic tendinopathic Achilles tendons, presence of T and B lymphocytes, natural killer cells and macrophages has been reported. Whether the…Abstract Number: 1878 • 2012 ACR/ARHP Annual Meeting
Cognitive Manifestations of Fibromyalgia and Lupus
Background/Purpose: Similar cognitive complaints for patients with fibromyalgia and systemic lupus erythematosus (SLE) have been reported; however, inherently different deficits can share superficial similarities. The…Abstract Number: 1839 • 2012 ACR/ARHP Annual Meeting
The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort
Background/Purpose: The European League Against Rheumatism recommends tight control of rheumatoid arthritis (RA). However, tight control of RA may depend on several factors, including patient…Abstract Number: 1840 • 2012 ACR/ARHP Annual Meeting
Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). Oral disease modifying anti-rheumatic drugs (DMARDs) are often used as a first-line treatment…Abstract Number: 1841 • 2012 ACR/ARHP Annual Meeting
Lower Than Expected Levels of DMARD Acquisition Immediately Pre and Post Biologic Initiation in Rheumatoid Arthritis Patients
Background/Purpose: Reports suggest that a large proportion of patients who acquire and use biologic DMARD agents (biologics) to treat Rheumatoid Arthritis (RA) do not acquire…Abstract Number: 1842 • 2012 ACR/ARHP Annual Meeting
Disease Activity and Treatment Strategies in Moderate Rheumatoid Arthritis Patient Population: Data From the Consortium of Rheumatology Researchers of North America
Background/Purpose: Studies on patients with severe rheumatoid arthritis (RA) are widely reported. However, limited data are available on patients with moderate disease activity (MOD). Recent…Abstract Number: 1843 • 2012 ACR/ARHP Annual Meeting
Predictors of Starting and Stopping Disease Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis: A 23 Year Longitudinal Cohort
Background/Purpose: DMARDs are the standard of care for rheumatoid arthritis (RA), however multiple studies find that not all patients use these agents. We examined predictors…Abstract Number: 1844 • 2012 ACR/ARHP Annual Meeting
Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries
Background/Purpose: In the treatment of patients with RA, EULAR recommends to initiate biologic DMARDs after failing synthetic DMARDs. However, biologics are costly, and it is…Abstract Number: 1845 • 2012 ACR/ARHP Annual Meeting
Inequalities Across 46 European Countries in Clinical Eligibility Criteria for the Start of A First (Reimbursed) Biologic in Patients with Rheumatoid Arthritis
Background/Purpose: In the treatment of patients with RA, strategies that include biologics have resulted in a better outcome for patients with regard to disease activity,…Abstract Number: 1846 • 2012 ACR/ARHP Annual Meeting
Observation of Persistence Rates and Potential Costs Savings Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northen Ireland Clinical Practice
Background/Purpose: Rheumatoid arthritis (RA) therapy in the UK is standardized by the National Institute for Health and Clinical Excellence (NICE). To be eligible for anti-TNF…Abstract Number: 1847 • 2012 ACR/ARHP Annual Meeting
Status of the Rheumatology Clinical Trials Portfolio: Data From Clinicaltrials.Gov
Background/Purpose: In an effort to provide a comprehensive listing of clinical trials Congress initiated the creation of the ClinicalTrials.gov (CT.gov) registry in 1997. In 2007…
ACR Meeting Abstracts